Currency effect amplifies Abilify's growth for Otsuka
This article was originally published in Scrip
Otsuka Holdings saw global sales of its top product, the atypical antipsychotic Abilify (aripiprazole), increase by 22% to JPY117.8bn ($1.22bn) in the fiscal first quarter ended 30 June, helped by currency effects and US growth.
You may also be interested in...
Join us for an audio catch-up on the latest key developments in the global biopharma industry, as reported by Scrip's global team, in this mini podcast version of Five Must-Know Things.
Plus deals involving Astellas/Actinium, Sosei/PharmEnable, Aadi/EOC Pharma, BeiGene/Strand, Chi-Med/Inmagene, Alteogen/Intas, Sosei/AbbVie, Y-Biologics/3D Medicines.
Given its ever-growing role as a critical component of the global biopharma industry, you can’t afford not to be up to speed on Asia. This selection of recent insights from our experienced on-the-ground team will help.